Promentis Pharmaceuticals, Inc. is a privately-held biopharmaceutical company based in Milwaukee, WI, focused on developing innovative therapies for neuropsychiatric disorders. Their initial focus is on trichotillomania, a prevalent disorder with no approved therapy, targeting glutamate signaling in brain regions associated with urge control and executive function.
With a world-class leadership team and a novel approach utilizing oral compounds that engage System xc -, Promentis Pharmaceuticals aims to address a range of psychiatric disorders, including obsessive-compulsive and addictive disorders, as well as other CNS conditions.
Generated from the website